Provider, Aviva, has reported that the number of critical illness (CI) claims it paid relating to prostate cancer between 2023 and 2025 increased by around 65%.
Last year, Aviva paid out over £43 million for prostate and testicular cancer claims across its individual CI and life insurance products. Specifically, £38m was paid out for prostate cancer in 2025 and £5m was paid out for testicular cancer. Prostate cancer represented 29% of individual cancer-related CI claims made by men, Aviva said while testicular cancer is less common, it has continued to affect men of all ages. This Men's Health Week, Aviva said its consumer research has suggested that many men are still not taking steps to detect cancer early. Around 29% of men said they...
To continue reading this article...
Join COVER for free
Signup and gain exclusive members-only insights
- Unlimited access to real-time news, key trend analysis and industry insights.
- Stay on top of the latest developments around health and wellbeing, diversity and inclusion and the cost of living crisis.
- Receive breaking news stories straight to your inbox in the daily newsletter.
- Members only access to monthly programme 'The COVER Review'
- Be the first to hear about our CPD accredited events and awards programmes.
